SEC Filing Summary: Spherix Incorporated (10-Q)
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for Spherix Incorporated for the period ended March 31, 2009. The company operates two segments: Biospherics, focused on developing "Naturlose" (tagatose) for Type 2 diabetes treatment, and Health Sciences, which provides technical and regulatory consulting. The company is a smaller reporting company with no debt obligations listed on the balance sheet.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Revenue | $360,670 | $142,908 |
| Net Loss | $(2,066,084) | $(1,914,234) |
| Loss Per Share (Basic/Diluted) | $(0.14) | $(0.13) |
| Operating Cash Flow | $(1,491,745) | $(1,979,531) |
| Cash and Equivalents (End of Period) | $7,778,180 | $9,372,689 |
| Total Assets | $10,525,697 | $12,261,236 |
| Working Capital | $8,778,981 | $10,845,829 |
Segment Performance: All revenue ($361,000) and operating profit ($163,000) were generated by the Health Sciences segment. The Biospherics segment reported an operating loss of $(1,625,000) with no revenue.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 152% year-over-year, driven entirely by the Health Sciences consulting segment.
- Increased R&D Costs: Research and development expenses rose to $1.56 million (from $1.03 million) due to the expansion of the Phase 3 clinical trial for Naturlose into India.
- Reduced SG&A: Selling, general, and administrative expenses decreased to $759,270 (from $1.1 million) following a headquarters relocation in 2008.
- Lower Interest Income: Interest income dropped to $24,447 (from $136,575) as cash reserves were deployed to fund clinical trials.
- Cash Burn: Net cash used in operating activities improved slightly to $(1.49) million compared to $(1.98) million in the prior year, though total cash decreased by $1.63 million during the quarter.
Outlook, Risks, and Management Commentary
- Clinical Trial Status: The Phase 3 trial for Naturlose is expected to complete in mid-to-late 2010, with interim analysis results anticipated in Q3 2009. Patient recruitment in the U.S. was slower than expected, prompting the expansion to India and a change in delivery method (powder sachets) to improve retention.
- Liquidity and Capital Needs: Management expects to expend approximately $7 million over the next 12 months ($5 million for trials). While current resources may suffice to complete the Phase 3 trial by mid-2010, they are insufficient to fund the subsequent FDA New Drug Application (NDA) or commercialization.
- Financing Strategy: The company intends to finance future activities through the 2007 sale proceeds of InfoSpherix and is considering raising additional funds via common stock sales. No meaningful offers to license the technology are expected until trial efficacy is established.
- Risks: Significant risks include the potential for trial delays, which could deplete funds before completion, and the uncertainty of securing additional capital. The company also faces the risk that the trial results may not demonstrate efficacy.
Investor Verification Checklist
- Verify the timeline and enrollment rates of the Phase 3 clinical trial in India versus the U.S.
- Confirm the sufficiency of the $7.8 million cash balance against the projected $7 million burn rate for the next 12 months.
- Monitor for announcements regarding interim analysis results expected in Q3 2009.
- Assess the company's progress in securing additional financing for the post-trial NDA phase.
- Review the Health Sciences segment's contract pipeline to ensure continued revenue stability.